Medicare reimbursement and the use of biologic agents: Incentives, access, the public good, and optimal care

Arthritis Care and Research

Volumn 62, Issue 3, 2010, Pages 293-295

  Ward, Michael M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; MEDICARE; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; BENCHMARKING; BIOLOGICAL FACTORS; HUMANS; MEDICARE PART B; MEDICARE PART D; REIMBURSEMENT, INCENTIVE; UNITED STATES;

EID: 77649209634     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20088     Document Type: Editorial

References (16)

1. Safran DG, Neuman P, Schoen C, Kitchman MS, Wilson IB, Cooper B, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. URL: http://content. healthaffairs.org/cgi/content/full/hlthaff.w5.152/DC1.
2. Neuman P, Kitchman Strollo M, Guterman S, Rogers WH, Li A, Rodday AM, et al. Medicare prescription drug benefits progress report: findings from a 2006 national survey of seniors. Health Affairs 2007;26:w630-43.
3. Iglehart JE. Medicare and drug pricing. N Engl J Med 2003; 348:1590-7.
4. US General Accounting Office. Medicare: payments for covered outpatient drugs exceed providers' cost. Washington (DC): US General Accounting Office; 2001.
5. US District Court of Massachusetts. Pharmaceutical industry average wholesale price litigation: findings of fact and conclusions of law. 2007. URL: http://jimedwardsnrx.files.wordpress.com/2009/06/download-abbotts-motion- against-the-doj-here.pdfFindings of fact and conclusions of law.
6. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9:S136-44.
7. Morgan DeWitt E, Glick HA, Albert DA, Joffe MM, Wolfe F. Medicare coverage of tumor necrosis factor α inhibitors as an influence on physician's prescribing behavior. Arch Intern Med 2006;166:57-63.
8. US Government Accountability Office. Medicare chemotherapy payments: new drug and administration fees are closer to providers' costs. Washington (DC): US Government Accountability Office; 2004.
9. Siegel J. Impact of the Medicare Prescription Drug Improvement and Modernization Act on the management of colorectal cancer. Am J Health Syst Pharm 2006;63 Suppl 2:S18-21.
10. US House of Representatives: Ways and Means Committee, Subcommittee on Health. Medicare payments for currently covered prescription drugs: statement of the American College of Rheumatology. 2002. URL: http://waysandmeans.house. gov/Legacy/health/107cong/10-3-02/107-84final.htm.
11. Friedman JY, Curtis LH, Hammill BG, Dhillon JK, Weaver CH, Biswas S, et al. The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care? Cancer 2007;110:2304-12.
12. Shea AM, Curtis LH, Hammill BG, DiMartino LD, Abernethy AP, Schulman KA. Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. JAMA 2008;300:189-96.
13. Doshi JA, Li P, Puig A. Impact of the Medicare Modernization Act of 2003 on utilization and spending for Medicare Part B-covered biologics in rheumatoid arthritis. Arthritis Care Res 2010;62:353-60.
14. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008;58:939-46.
15. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-229.
16. Polinski JM, Mohr PE, Johnson L. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. Arthritis Rheum 2009;61:745-54.